A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
The prospects for Chinese competitors, ongoing controversy in cervical cancer and a super-fast approval take centre stage.
The Biontech/Pfizer pandemic vaccine sneaks into the 10 biggest-ever cumulative sellers, while Merck & Co’s Keytruda vaults to second place.
But the pace of biopharma asset deals dips. Are the two trends related?
The agency takes its time – particularly with diagnostics.
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.